Biohaven Q1 net loss $70.5M; cash $392M; pipeline progress, TYK2/JAK1 license acquired

Biohaven Ltd.

2023-Q1 EPS reported -$1.03

Net loss of $70.5M ($1.03/share); non-GAAP adjusted net loss $66.7M ($0.98/share).
Cash and marketable securities $392.0M at March 31, 2023, down from $467.9M at Dec 31, 2022.
Acquired exclusive global rights (ex-China) to TYK2/JAK1 inhibitor BHV-8000; Phase 1 start planned in 2023.
Appointed Nick Kozauer (former FDA Division Director) as SVP of Clinical Development and Regulatory Strategy.
Anticipates H2 2023: Phase 2/3 for BHV-7000 in epilepsy/bipolar; IND submissions for BHV-7010, -2100, -1300.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Biohaven Ltd. reported financial results for the first quarter ended March 31, 2023.

Period: the first quarter ended March 31, 2023
Result: reported results

Exact text from the filing

On May 12, 2023, Biohaven Ltd. (the “ Registrant ”) issued a press release announcing its financial results for the first quarter ended March 31, 2023.

View on SEC.gov

Browse all earnings releases →

Biohaven Ltd. filing history →

Source: SEC EDGAR

accession 0001935979-23-000033

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.